Gemfibrozil Therapy in Primary Hypertriglyceridemia Associated With Coronary Heart Disease: Effects on Metabolism of Low-Density Lipoproteins

Research output: Contribution to journalArticle

61 Scopus citations

Abstract

Certain primary hypertriglyceridemias cause abnormalities in lipoproteins that seemingly predispose patients to coronary heart disease. We examined metabolism of low-density lipoproteins (LDL) in 11 men with both hypertriglyceridemia and coronary heart disease and compared them with that of controls. The LDL turnover was measured during placebo and gemfibrozil therapy. With placebo, LDL-cholesterol level usually was normal, but production and fractional clearance of LDL were high. The LDL composition also was abnormal. Gemfibrozil reduced triglycerides, lowered production and fractional clearance of LDL, and normalized LDL composition. The LDL-cholesterol level usually rose, but generally not to abnormally high levels. Therefore, normalization of LDL metabolism and marked reduction of triglycerides by gemfibrozil suggest benefit to hypertriglyceridemic patients who are at high risk for coronary heart disease. However, when LDL-cholesterol level rises excessively, gemfibrozil may not be sufficient therapy.

Original languageEnglish (US)
Pages (from-to)2398-2403
Number of pages6
JournalJAMA: The Journal of the American Medical Association
Volume253
Issue number16
DOIs
StatePublished - Apr 26 1985

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Gemfibrozil Therapy in Primary Hypertriglyceridemia Associated With Coronary Heart Disease: Effects on Metabolism of Low-Density Lipoproteins'. Together they form a unique fingerprint.

  • Cite this